Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
EBS Emergent BioSolutions Inc. daily Stock Chart
EBS [NYSE]
Emergent BioSolutions Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E27.58 EPS (ttm)1.37 Insider Own5.10% Shs Outstand41.27M Perf Week0.61%
Market Cap1.56B Forward P/E16.89 EPS next Y2.24 Insider Trans-6.45% Shs Float33.38M Perf Month6.71%
Income67.80M PEG1.65 EPS next Q0.41 Inst Own87.80% Short Float7.98% Perf Quarter18.05%
Sales512.20M P/S3.05 EPS this Y-34.50% Inst Trans0.41% Short Ratio9.34 Perf Half Y24.70%
Book/sh15.13 P/B2.50 EPS next Y45.40% ROA7.70% Target Price43.60 Perf Year37.76%
Cash/sh7.65 P/C4.95 EPS next 5Y16.67% ROE12.40% 52W Range24.47 - 38.74 Perf YTD15.32%
Dividend- P/FCF36.86 EPS past 5Y14.80% ROI8.00% 52W High-2.25% Beta1.30
Dividend %- Quick Ratio6.00 Sales past 5Y12.30% Gross Margin69.00% 52W Low54.76% ATR0.95
Employees1098 Current Ratio7.00 Sales Q/Q10.50% Oper. Margin21.50% RSI (14)60.37 Volatility2.01% 2.37%
OptionableYes Debt/Eq0.40 EPS Q/Q281.50% Profit Margin14.40% Rel Volume0.53 Prev Close37.87
ShortableYes LT Debt/Eq0.40 EarningsAug 03 AMC Payout0.00% Avg Volume285.14K Price37.87
Recom1.80 SMA202.72% SMA505.50% SMA20017.75% Volume0 Change0.00%
Jun-28-16Reiterated Singular Research Buy $44 → $40
Apr-15-16Initiated Chardan Capital Markets Buy $47
Mar-28-16Initiated Singular Research Buy $44
Feb-19-16Initiated Wells Fargo Outperform
May-15-14Initiated Summer Street Research Buy $35
May-31-11Reiterated WBB Securities Strong Buy $20.50 → $30
Jan-10-11Reiterated Wedbush Outperform $27 → $32
Nov-05-10Reiterated Wedbush Outperform $22 → $27
Aug-18-10Upgrade WBB Securities Buy → Strong Buy $20.50
Aug-06-10Reiterated Caris & Company Buy $25 → $23
Jul-14-10Upgrade WBB Securities Hold → Buy $15.60 → $20.50
May-06-10Downgrade WBB Securities Buy → Hold $15.60
Dec-28-09Reiterated Caris & Company Buy $17 → $19
Mar-23-09Reiterated Caris & Company Buy $25 → $21
Mar-20-09Initiated Wedbush Morgan Buy $26
Mar-06-09Upgrade Caris & Company Average → Buy
Feb-17-09Downgrade Caris & Company Above Average → Average $27 → $25
Dec-18-08Reiterated Caris & Company Above Average $20 → $27
Oct-14-08Initiated Caris & Company Above Average $18
Jan-03-07Initiated HSBC Securities Overweight $18
Sep-18-17 08:00AM  Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure GlobeNewswire
Sep-12-17 08:07AM  See what the IHS Markit Score report has to say about Emergent Biosolutions Inc. Markit
Sep-11-17 08:00AM  Hodges Mutual Fund Aims For Elite Status With Bets On Leading Stocks Like Emergent BioSolutions Investor's Business Daily
Sep-04-17 04:07AM  Emergent Biosolutions (EBS) Up 6% Since Earnings Report: Can It Continue? Zacks
Aug-23-17 04:15PM  ETFs with exposure to Emergent BioSolutions, Inc. : August 23, 2017 Capital Cube
Aug-22-17 08:04AM  See what the IHS Markit Score report has to say about Emergent Biosolutions Inc. Markit
Aug-16-17 08:02AM  See what the IHS Markit Score report has to say about Emergent Biosolutions Inc. Markit
Aug-14-17 08:03AM  See what the IHS Markit Score report has to say about Emergent Biosolutions Inc. Markit
Aug-13-17 10:55AM  Edited Transcript of EBS earnings conference call or presentation 3-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-11-17 10:01AM  Biotech movers: Ionis Drops After GSK Bows Out of Partnership TheStreet.com
08:02AM  See what the IHS Markit Score report has to say about Emergent Biosolutions Inc. Markit
Aug-10-17 12:22PM  Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 Capital Cube
Aug-09-17 08:05AM  See what the IHS Markit Score report has to say about Emergent Biosolutions Inc. Markit
Aug-07-17 03:43PM  Emergent Biosolutions Inc Diversifies Its Revenue Motley Fool
Aug-05-17 01:10AM  Emergent Biosolutions misses 2Q profit forecasts Associated Press
Aug-04-17 04:19PM  Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y Zacks
03:55AM  Erste CEO on Earnings, Czech Housing Market, Brexit Bloomberg Video
Aug-03-17 04:15PM  Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance GlobeNewswire
01:20PM  Investor Network: Emergent BioSolutions Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 04:34PM  ETFs with exposure to Emergent BioSolutions, Inc. : August 1, 2017 Capital Cube
Jul-31-17 04:15PM  Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense GlobeNewswire
Jul-26-17 04:17PM  VALNEVA and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus GlobeNewswire
04:15PM  Emergent BioSolutions Secures Exclusive Worldwide Rights to Valnevas Zika Vaccine Technology GlobeNewswire
Jul-20-17 06:19PM  Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab Zacks
03:10PM  Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million American City Business Journals
07:00AM  Emergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August 3, 2017 GlobeNewswire
Jul-19-17 04:15PM  Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK GlobeNewswire
Jul-17-17 12:26PM  Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit Zacks
Jul-14-17 01:50PM  Emergent acquires Sanofi smallpox vaccine in deal worth up to $125 million American City Business Journals
07:00AM  Emergent BioSolutions to Acquire ACAM2000® Business From Sanofi GlobeNewswire
Jun-09-17 11:37AM  Why Is Emergent Biosolutions (EBS) Up 3.9% Since the Last Earnings Report? Zacks
Jun-06-17 11:41AM  ETFs with exposure to Emergent BioSolutions, Inc. : June 6, 2017 Capital Cube
May-24-17 08:12AM  Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : May 24, 2017 Capital Cube
May-22-17 01:35PM  ETFs with exposure to Emergent BioSolutions, Inc. : May 22, 2017 Capital Cube
May-19-17 09:38AM  Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 Capital Cube
May-11-17 07:00AM  Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be Available GlobeNewswire
May-10-17 09:25AM  Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore GlobeNewswire
May-09-17 07:40PM  Edited Transcript of EBS earnings conference call or presentation 4-May-17 9:00pm GMT Thomson Reuters StreetEvents +5.56%
07:00AM  Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA GlobeNewswire
May-08-17 04:20PM  Emergent Biosolutions Inc. Moves Things Around, Still Sees Growth Motley Fool
09:10AM  Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : May 8, 2017 Capital Cube
May-04-17 07:10PM  Emergent Biosolutions beats 1Q profit forecasts Associated Press
04:15PM  Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance GlobeNewswire
Apr-27-17 04:45PM  Emergent BioSolutions, Inc. Value Analysis (NYSE:EBS) : April 27, 2017 Capital Cube
Apr-26-17 08:38AM  Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : April 26, 2017 Capital Cube
Apr-20-17 07:00AM  Emergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017 GlobeNewswire
Mar-31-17 07:00AM  Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin GlobeNewswire
Mar-20-17 08:20AM  Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : March 20, 2017 Capital Cube
08:20AM  Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : March 20, 2017
05:40AM  Emergent BioSolutions gets $100 million anthrax contract from feds at bizjournals.com
05:40AM  Emergent BioSolutions gets $100 million anthrax contract from feds American City Business Journals
Mar-17-17 09:14AM  EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
07:00AM  Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile GlobeNewswire
Mar-16-17 05:50PM  Local drug company stocks react to Trump's proposed cuts to NIH, FDA at bizjournals.com
05:50PM  Local drug company stocks react to Trump's proposed cuts to NIH, FDA American City Business Journals
Mar-13-17 08:15AM  Blog Coverage Galapagos Announced New Phase-II Studies Led by Filgotinib Collaboration Partner Gilead Sciences Accesswire
Mar-09-17 07:35AM  Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : March 9, 2017 Capital Cube
07:35AM  Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : March 9, 2017
Mar-04-17 01:04PM  EMERGENT BIOSOLUTIONS INC. Financials
Mar-02-17 01:15PM  Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017 Capital Cube
01:15PM  Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017
Feb-28-17 06:18AM  EMERGENT BIOSOLUTIONS INC. Files SEC form 10-K, Annual Report
Feb-27-17 11:03AM  Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017
Feb-24-17 06:31PM  Emergent BioSolutions Inc Sets its Goal Motley Fool
06:31PM  Emergent BioSolutions Inc Sets its Goal at Motley Fool
03:25PM  Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
Feb-23-17 10:18PM  Edited Transcript of EBS earnings conference call or presentation 23-Feb-17 10:00pm GMT
07:01PM  Emergent Biosolutions posts 4Q profit
05:27PM  EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
05:00PM  Emergent BioSolutions Inc Earnings Call scheduled for 5:00 pm ET today
04:15PM  Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals GlobeNewswire
07:07AM  Q4 2016 Emergent BioSolutions Inc Earnings Release - After Market Close
Feb-21-17 05:12PM  EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
Feb-13-17 07:00AM  Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics GlobeNewswire
Feb-09-17 07:00AM  Emergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a Conference Call on February 23, 2017 GlobeNewswire
Feb-01-17 07:00AM  Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for Dengue GlobeNewswire
Jan-27-17 07:00AM  Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThrax GlobeNewswire
Jan-23-17 12:04PM  3 Cheap Growth Stocks You Can Buy Right Now at Motley Fool
09:45AM  Lawsuit for Investors in Shares of Emergent Biosolutions Inc (EBS) Announced by Shareholders Foundation Accesswire
Jan-12-17 07:55AM  Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : January 12, 2017
Jan-11-17 11:10PM  D.C.-area biotech stocks fall on Trump's tough talk on industry at bizjournals.com
Jan-10-17 02:40PM  Emergent Down on '17 View, Posts Preliminary '16 Results
Jan-09-17 08:11AM  EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur -7.56%
07:00AM  Emergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial Outlook GlobeNewswire
Dec-29-16 04:15PM  Emergent BioSolutions to Participate in First Quarter 2017 Investor Conferences GlobeNewswire
Dec-16-16 06:06AM  Is Consolidated Communications Holdings Inc (CNSL) A Good Stock To Buy? at Insider Monkey
Dec-15-16 10:33AM  Technical-analysis trading: Four stocks that may be moving higher at MarketWatch
Dec-14-16 11:58AM  Four Stocks Moving Higher at Forbes
11:26AM  Hedge Funds Are Dumping Emergent Biosolutions Inc (EBS) at Insider Monkey
08:21AM  Why stock in this Gaithersburg biotech is up more than 25 percent at bizjournals.com
Dec-13-16 10:31AM  Emergent BioSolutions, Inc. Value Analysis (NYSE:EBS) : December 13, 2016
Dec-12-16 03:13PM  Emergent BioSolutions, Inc.: Gathering momentum, can it sustain its performance?
08:25AM  Emergent BioSolutions (EBS) in Focus: Stock Rises 18.9%
07:23AM  Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : December 12, 2016
07:00AM  Emergent BioSolutions Receives Health Canada Approval for Botulism Antitoxin GlobeNewswire
Dec-09-16 03:24PM  Why Emergent Biosolutions Inc. Stockpiled a Higher Price Today at Motley Fool +18.92%
09:37AM  Should You Get Rid of Emergent BioSolutions (EBS) Now?
Dec-08-16 05:30PM  Emergent BioSolutions Inc Business Update Call scheduled for 5:30 pm ET today
05:28PM  EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
05:13PM  Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile GlobeNewswire
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company's marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. Its investigational stage product candidates include NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 for Burkholderia pseudomallei; FLU-IG (NP025), a human polyclonal antibody therapeutic being developed to treat seasonal influenza; ZIKA-IG (NP024), a human polyclonal antibody therapeutic being developed as a prophylaxis for Zika infections; and FILOV (NP026), an equine polyclonal antibody therapeutic being developed to treat Ebola infections. In addition, the company provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
El-Hibri FuadChairmanSep 14Sale38.5023,547906,5601,580,216Sep 14 05:27 PM
El-Hibri FuadChairmanSep 12Sale38.501,45355,9411,603,763Sep 14 05:27 PM
Havey AdamEVP, Business OperationsSep 08Option Exercise22.037,885173,70733,931Sep 12 03:56 PM
Havey AdamEVP, Business OperationsSep 08Sale37.067,885292,24326,046Sep 12 03:56 PM
El-Hibri FuadChairmanSep 07Sale37.5016,439616,4631,605,216Sep 08 02:31 PM
El-Hibri FuadChairmanSep 05Sale37.503,100116,2501,621,655Sep 06 06:21 PM
Abdun-Nabi DanielPresident & CEOAug 31Option Exercise22.0315,000330,450219,134Sep 05 05:16 PM
Abdun-Nabi DanielPresident & CEOAug 31Sale37.2115,000558,150204,134Sep 05 05:16 PM
El-Hibri FuadChairmanAug 31Sale37.505,461204,7881,624,755Sep 01 07:31 PM
Hauer Jerome MDirectorAug 15Sale35.8310,776386,14918,645Aug 17 04:32 PM
El-Hibri FuadChairmanJul 27Sale36.5025,000912,5001,630,216Jul 28 02:12 PM
El-Hibri FuadChairmanJul 20Sale35.5025,000887,5001,655,216Jul 21 05:27 PM
Havey AdamEVP, Biodefense DivisonApr 03Sale28.6211,419326,80826,046Apr 04 04:14 PM
Hauer Jerome MDirectorMar 08Sale31.272,57680,55816,009Mar 10 04:18 PM
Abdun-Nabi DanielPresident & CEOFeb 27Option Exercise30.633,662112,167192,824Mar 01 08:26 PM
Bailey SueDirectorJan 17Option Exercise14.7319,424286,18840,553Jan 19 09:33 PM
Bailey SueDirectorJan 17Sale29.7819,424578,42535,818Jan 19 09:33 PM
Havey AdamEVP, Biodefense DivisonJan 17Sale29.758,438251,00134,333Jan 19 09:15 PM
Abdun-Nabi DanielPresident and CEOJan 10Option Exercise14.5138,006551,467217,402Jan 12 09:59 PM
Abdun-Nabi DanielPresident and CEOJan 10Sale31.2828,240883,296189,162Jan 12 09:59 PM
Richard RonaldDirectorDec 13Sale34.095,900201,10715,151Dec 15 08:48 PM
open in yahoo | open in reuters | open in google